Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Catherine Page

Nurse Practitioner, Family Jackson, MS Nurse Practitioner

NPI 1538699483 CMS profile 10814443

971 Lakeland Dr Ste 950, Jackson, MS 39216

Open in the dashboard

General payments

$14,161

821 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Catherine Page of Jackson, MS is reported in the CMS Open Payments database as having received $14,161 across 821 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,236 130
2024 General $3,259 189
2023 General $3,497 193
2022 General $3,416 187
2021 General $1,753 122

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Catherine Page
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Catherine Page were reported at $2,236. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Catherine Page Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,753 $124 $35–$379 $132
2022 $3,416 $141 $44–$430 $149
2023 $3,497 $154 $49–$476 $160
2024 $3,259 $165 $51–$504 $164
2025 $2,236 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $4,295 268 payments
  2. AbbVie, Inc. $2,849 163 payments
  3. UCB, Inc. $1,443 81 payments
  4. Janssen Biotech, Inc. $1,052 59 payments
  5. Novartis Pharmaceuticals Corporation $1,003 68 payments
  6. Mallinckrodt Hospital Products Inc. $521 21 payments
  7. Pfizer Inc. $505 28 payments
  8. AstraZeneca Pharmaceuticals LP $351 22 payments
  9. Genentech USA, Inc. $327 19 payments
  10. Lilly USA, LLC $324 19 payments
  11. Other $1,490 73 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,017 819 payments
  2. Education $144 2 payments
Products named General payments · program years 2021–2025
  1. Otezla $2,205 133 payments
  2. RINVOQ $2,054 106 payments
  3. Enbrel Inflammation $1,443 95 payments
  4. Enbrel Inflammation $1,313 91 payments
  5. Cimzia $1,235 69 payments
  6. COSENTYX $796 56 payments
  7. TREMFYA $747 39 payments
  8. SKYRIZI $545 38 payments
  9. ACTHAR $521 21 payments
  10. EVENITY $519 39 payments
  11. Other $6,266 373 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

1,220

Median for Nurse Practitioner: 389

Drug cost

$394,349

Median for Nurse Practitioner: $21,885

Branded share of claims

26.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 30 $288,782
Cosentyx Sensoready Pen Secukinumab Brand 12 $86,833
Hydroxychloroquine Sulfate Generic 407 $9,250
Methotrexate Methotrexate Sodium Brand 284 $3,451
Leflunomide Generic 23 $1,698
Prednisone Generic 175 $1,137
Celecoxib Generic 53 $703
Mycophenolate Mofetil Generic 11 $544
Gabapentin Generic 31 $365
Sulfasalazine Generic 22 $345

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$90,260

Of which drugs: $63,912

Medicare patients

204

Average age 73

Services billed

13,324

160 women, 44 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 31%
Ischemic heart disease 28%
Osteoporosis 28%
Depression 15%
Chronic kidney disease 14%
Atrial fibrillation 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 14 840 $16,871
Injection, methylprednisolone acetate, 1 mg J1010 Office 30 2,640 $254
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 24 208 $17

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Otezla
$346 — —
Enbrel
$336 — —
SKYRIZI
$324 — —
Cimzia
$320 — —
COSENTYX
$239 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

821 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record